Trophic serves as a strategic partner for all aspects of communications for life science companies. We apply a deep understanding of both the science and business of drug development and the capital needed for success. Based on breadth and depth of experience, Trophic has become the go-to advisory for presenting corporate stories and scientific concepts. Current client portfolio ranges from biotech start-ups, listed biopharmas and small and large pharmaceutical companies.

TROPHIC TWITTER FEED

Follow us on Twitter to stay tuned on biotech news and the inner workings of the Trophic team

Congratulations to Abalos Therapeutics on their €12M #SeriesA financing & company #launch! https://t.co/HFTzYzxem2

Abalos is harnessing #arenaviruses to activate the immune system against #cancer cells. Check our their brand new #website to learn more: https://t.co/MUHCvhfFjC

Today we announced the first patient enrolled in the Phase I/II trial testing our lead candidate, #NOXA12, with #radiotherapy in newly diagnosed #braincancer. See the full announcement here: https://t.co/g5bxhSeRQK

Birthday boy, @jacobvinfo spotted with outstandingly smooth cognac & Gretchen's homemade apple crisp. Wishing you all the best on this perfect fall day! #happybirthday

Load More...